jRCT2080225264
已完成
1 期
ONO-7912 Phase I Study A multicenter, open-label, uncontrolled study in pancreatic cancer (ONO-7912-01)
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- ONO PHARMACEUTICAL CO., LTD.
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- -
- 状态
- 已完成
- 最后更新
- 11个月前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Patients diagnosed with invasive pancreatic ductal carcinoma determined as adenocarcinoma histologically or cytologically
- •Patients who received one regimen of chemotherapy including gemcitabine for pancreatic cancer.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- •Have a life expectancy of at least 90 days
排除标准
- •Patients in whom oxaliplatin, irinotecan, fluorouracil, or levofolinate calcium is contraindicated
- •Patients with clinically relevant diarrhea (including watery stools)
- •Patients with grade >=2 peripheral motor neuropathy or peripheral sensory neuropathy
- •Patients who have received ONO-7912
结局指标
主要结局
-
safety Tolerability, safety
研究点 (1)
Loading locations...
相似试验
暂停
不适用
ONO-7913-02 : ONO-7913 Phase 1 StudyjRCT2031210139Ono Pharmaceutical Co.,LTD12
进行中（未招募）
不适用
ONO-7913-04: ONO-7913 Phase 1 StudyjRCT2051210038Ono Pharmaceutical Co.,LTD60
进行中（未招募）
不适用
ONO-7913-03: ONO-7913 Phase 1 StudyjRCT2031210172Ono Pharmaceutical Co.,LTD30
已完成
不适用
ONO-7914-01:Phase I study of ONO-7914 alone and in combination with ONO-4538 in patients with solid tumorsjRCT2031210530Ono Pharmaceutical Co.,LTD204
进行中（未招募）
不适用
ONO-7475-03 : ONO-7475 Phase 1 StudyjRCT2051210045Ono Pharmaceutical Co.,LTD75